Kim Linton

5.5k total citations · 1 hit paper
122 papers, 2.2k citations indexed

About

Kim Linton is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Kim Linton has authored 122 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pathology and Forensic Medicine, 69 papers in Oncology and 42 papers in Genetics. Recurrent topics in Kim Linton's work include Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (37 papers) and CAR-T cell therapy research (34 papers). Kim Linton is often cited by papers focused on Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (37 papers) and CAR-T cell therapy research (34 papers). Kim Linton collaborates with scholars based in United Kingdom, United States and Denmark. Kim Linton's co-authors include John Radford, Pam McKay, Tim Illidge, Kate Cwynarski, David Cunningham, Richard Byers, Michael Roost Clausen, Pieternella J. Lugtenburg, Martin Hutchings and David Lewis and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Kim Linton

115 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Michael Roost Clausen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kim Linton United Kingdom	24	1.2k	1.1k	542	421	408	122	2.2k
Alejandro Martı́n Spain	25	861 0.7×	1.4k 1.3×	533 1.0×	845 2.0×	233 0.6×	128	2.8k
Jonathon B. Cohen United States	23	1.7k 1.5×	1.6k 1.5×	725 1.3×	252 0.6×	406 1.0×	131	2.4k
Paolo F. Caimi United States	23	948 0.8×	1.5k 1.4×	423 0.8×	467 1.1×	211 0.5×	209	2.2k
Nishitha Reddy United States	21	1.4k 1.2×	1.0k 0.9×	1.0k 1.9×	378 0.9×	222 0.5×	116	2.3k
Mark Roschewski United States	25	1.4k 1.2×	1.3k 1.3×	627 1.2×	779 1.9×	368 0.9×	131	2.9k
Lynn Navale United States	17	863 0.7×	1.7k 1.5×	212 0.4×	387 0.9×	137 0.3×	59	2.1k
Bastian von Tresckow Germany	31	2.2k 1.9×	2.2k 2.0×	432 0.8×	383 0.9×	844 2.1×	159	3.6k
Tara Baetz Canada	20	514 0.4×	904 0.8×	261 0.5×	317 0.8×	155 0.4×	71	1.5k
Stefan Dirnhofer Switzerland	22	548 0.5×	539 0.5×	324 0.6×	367 0.9×	169 0.4×	89	1.6k
Nilanjan Ghosh United States	28	939 0.8×	1.4k 1.3×	424 0.8×	583 1.4×	128 0.3×	160	2.4k

Countries citing papers authored by Kim Linton

Since Specialization

Citations

This map shows the geographic impact of Kim Linton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Linton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Linton more than expected).

Fields of papers citing papers by Kim Linton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Linton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Linton. The network helps show where Kim Linton may publish in the future.

Co-authorship network of co-authors of Kim Linton

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Linton. A scholar is included among the top collaborators of Kim Linton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Linton. Kim Linton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bachy, Emmanuel & Kim Linton. (2025). Frontline treatment of follicular lymphoma: what will it take to change current practice?. Blood. 146(15). 1770–1781.

El‐Sharkawi, Dima, David Lewis, Zulfa Omer, et al.. (2025). IBCL-675: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM). Clinical Lymphoma Myeloma & Leukemia. 25. S825–S825.

McIlroy, Graham, Siân Lax, Charlotte Gaskell, et al.. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer. 24(1). 370–370. 1 indexed citations

Karimi, Yasmin, Catherine Thiéblemont, Hervé Ghesquières, et al.. (2024). Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7039–7039. 5 indexed citations

Vose, Julie M., Chan Y. Cheah, Michael Roost Clausen, et al.. (2024). 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma. Blood. 144(Supplement 1). 4480–4480. 8 indexed citations

Vose, Julie M., Umberto Vitolo, Pieternella J. Lugtenburg, et al.. (2024). EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.. Journal of Clinical Oncology. 42(16_suppl). 7015–7015. 9 indexed citations

Falchi, Lorenzo, Anna Sureda, Sirpa Leppä, et al.. (2024). Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial. Blood. 144(Supplement 1). 342–342. 5 indexed citations

Falchi, Lorenzo, Fritz Offner, Sven de Vos, et al.. (2024). Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial. Blood. 144(Supplement 1). 581–581. 7 indexed citations

Linton, Kim, Lena Specht, Astrid Pavlovsky, et al.. (2023). Personalised therapy in follicular lymphoma – is the dial turning?. Hematological Oncology. 42(6). e3205–e3205. 4 indexed citations

10.

Crosbie, Philip, et al.. (2023). Pilot study of lung cancer screening for survivors of Hodgkin lymphoma. Haematologica. 109(10). 3305–3313. 1 indexed citations

11.

Linton, Kim, Francesco Forconi, David Lewis, et al.. (2023). Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies. Hematological Oncology. 41(S2). 573–574. 4 indexed citations

12.

Walewska, Renata, Toby A. Eyre, Sally F. Barrington, et al.. (2023). Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. British Journal of Haematology. 204(1). 86–107. 8 indexed citations

13.

Falchi, Lorenzo, Michael Roost Clausen, Fritz Offner, et al.. (2023). HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE. Hematological Oncology. 41(S2). 207–208. 2 indexed citations

14.

Gibb, Adam, Sarah Pirrie, Kim Linton, et al.. (2020). Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). British Journal of Haematology. 193(1). 63–71. 25 indexed citations

15.

Radford, John, Felipe A. Castro, Anshuman Chaturvedi, et al.. (2019). Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre. Blood. 134(Supplement_1). 2917–2917. 5 indexed citations

16.

Fergie, Martin, Catharine West, Kim Linton, et al.. (2018). Quantifying cell-type interactions and their spatial patterns as prognostic biomarkers in follicular lymphoma. Research Explorer (The University of Manchester). 22. 15–15. 2 indexed citations

17.

Lim, Sean H., Kim Linton, Graham P. Collins, et al.. (2018). RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. Trials. 19(1). 619–619. 8 indexed citations

18.

Schorb, Elisabeth, Benjamin Kasenda, Teresa Calimeri, et al.. (2017). Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice. Blood. 130. 376–376. 2 indexed citations

19.

Rose, Chris J., et al.. (2013). A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers. Journal of Pathology Informatics. 4(2). 4–4. 11 indexed citations

20.

Greystoke, Alastair, Kim Linton, Tim Illidge, et al.. (2008). Changes in serological biomarkers (BM) of cell death during chemotherapy (CT) in patients with lymphoma. Annals of Oncology. 19. 169–169. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact